Debate: Should DLBCL Patients be Treated Differently Based on Cell of Origin? - Yes 

Filmed on location in New York during the Great Debates & Updates in Hematologic Malignancies 2015, this webcast is part of a series that focuses on controversial areas in the management of hematologic malignancies as nationally-recognized thought leaders take opposing sides on topics of clinical interest.
In this presentation, Dr. Richard I. Fisher argues that Diffuse Large B-Cell Lymphoma (DLBCL) patients should be treated differently today based on cell of origin (Germinal vs. Non-Germinal Center).
© 2015 Imedex, LLC.